Table 2.
Prevalence of thyroid dysfunctions in placebo and Se groups at different weeks of gestation
| Gestational week | Placebo group | Se group | P valuea | ||
|---|---|---|---|---|---|
| No. in group | No. with dysfunction n (%) | No. in group | No. with dysfunction n (%) | ||
| Tg-Ab > 115 kU/l | |||||
| 12 weeks | 110 | 11 (10) | 113 | 11 (9.7) | 0.947 |
| TPO-Ab ≥ 35 kU/l | |||||
| 12 weeks | 113 | 15 (13.3) | 115 | 10 (8.7) | 0.269 |
| 20 weeks | 112 | 12 (10.7) | 109 | 8 (7.3) | 0.382 |
| 35 weeks | 109 | 7 (6.4) | 105 | 6 (5.7) | 0.828 |
| TPO-Ab ≥ 100 kU/l | |||||
| 12 weeks | 113 | 8 (7.1) | 115 | 6 (5.2) | 0.757 |
| 20 weeks | 112 | 7 (6.3) | 109 | 3 (2.8) | 0.333 |
| 35 weeks | 109 | 3 (2.8) | 105 | 0 (0) | 0.247 |
| Subclinical hypothyroidism | |||||
| 12 weeks | 113 | 12 (10.6) | 115 | 10 (8.7) | 0.623 |
| 20 weeks | 112 | 13 (11.6) | 108 | 7 (6.5) | 0.186 |
| 35 weeks | 109 | 13 (11.9) | 106 | 16 (15.1) | 0.479 |
| Isolated hypothyroxinemia | |||||
| 12 weeks | 113 | 1 (0.9) | 115 | 2 (1.7) | 1.000 |
| 20 weeks | 112 | 2 (1.8) | 108 | 3 (2.8) | 0.679 |
| 35 weeks | 109 | 10 (9.2) | 106 | 10 (9.4) | 0.948 |
a P values were from Chi-square test or Fisher’s exact test to compare placebo group versus Se group